A 21-month-old girl presented with ureteral triplication, representing an exceptional variant of Smith's type 1. One ureter was intravesical and the other 2 were extravesical (bladder neck and vaginal).
P=0.005) was significantly associated with the higher response rate to gefitinib. Progression-free survival (6.6 vs. 3.3 months; p=0.246) and overall survival (8.1 vs. 8.6 months; p=0.397) were similar between patients with EGFR mutations and those with wild-type EGFR. Conclusion: Clinical response to gefitinib in this study was linked to the presence of EGFR mutations. Given the limitation of small sample size, EGFR mutations were not associated with the specific clinical predictors for gefitinib responsiveness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.